Uniqure NV (QURE)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.67B
Last updated: Nov 17, 2026 at 11:06 AM ET
Uniqure NV (QURE) Competitors
The companies most similar to Uniqure NV are Ultragenyx (RARE), Pharvaris BV (PHVS) and Nurix Therapeutics (NRIX). By market cap, Uniqure NV ranks 6th of the 13 companies on this page; Pharvaris BV (PHVS) is the largest at $2.36B. The median P/E of the 4 companies with a P/E is 27.3x.
Peer Comparison
QURE's ROIC of -57.9% is below the peer median of -34.4%, and its revenue growth of 40.4% is above the median of 11.0%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Uniqure NV (QURE) | $1.67B | N/A | 75.8x | 0.0% | -57.9% | 40.4% | 0.00% |
| Ultragenyx (RARE) | $1.64B | N/A | 2.2x | -71.8% | N/A | 8.1% | 0.00% |
| Pharvaris BV (PHVS) | $2.36B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Nurix Therapeutics Inc (NRIX) | $1.69B | 6.4x | 2.3x | 42.0% | N/A | 8426.0% | 0.00% |
| Nuvation Bio Inc (NUVB) | $1.41B | N/A | 6.7x | -67.4% | -18.7% | 242.6% | 0.00% |
| CureVac NV (CVAC) | $1.05B | N/A | 1.8x | 182.1% | N/A | -89.0% | 0.00% |
| Pharming Group NV (PHAR) | $891.80M | 39.3x | 2.4x | 6.3% | 7.9% | 20.8% | 0.00% |
| Aurinia Pharmaceuticals Inc (AUPH) | $2.11B | 15.2x | 6.4x | 97.7% | N/A | 13.9% | 0.00% |
| UroGen Pharma Ltd (URGN) | $1.28B | N/A | 5.7x | -26.3% | -73.7% | 223.9% | 0.00% |
| Vera Therapeutics Inc (VERA) | $2.03B | N/A | 189.3x | 0.0% | -83.0% | 0.0% | 0.00% |
| Trevi Therapeutics Inc (TRVI) | $1.95B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Precigen Inc (PGEN) | $1.63B | 98.6x | 9.9x | 15.5% | 18.9% | 2438.0% | 0.00% |
| Intellia Therapeutics Inc (NTLA) | $1.36B | N/A | 26.1x | 0.0% | -50.0% | -48.0% | 0.00% |
| Peer median | $1.63B | 27.3x | 6.0x | 0.0% | -34.4% | 11.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Uniqure NV, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Ultragenyx (RARE) | Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development... | RARE competitors |
| Pharvaris BV (PHVS) | Pharvaris NV, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of rare disease therapies. | PHVS competitors |
| Nurix Therapeutics Inc (NRIX) | Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development... | NRIX competitors |
| Nuvation Bio Inc (NUVB) | Nuvation Bio Inc., a clinical-stage biopharmaceutical company, is focused on developing therapeutic candidates for oncology. | NUVB competitors |
| CureVac NV (CVAC) | CureVac NV, a clinical-stage biopharmaceutical company, is focused on developing various transformative drugs based on messenger ribonucleic acid (mRNA). | |
| Pharming Group NV (PHAR) | Pharming Group NV, a specialty pharmaceutical company, develops products for the treatment of rare diseases and unmet medical needs in the United States... | PHAR competitors |
| Aurinia Pharmaceuticals Inc (AUPH) | Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and markets therapies to treat various diseases with unmet medical needs in Japan and China. | AUPH competitors |
| UroGen Pharma Ltd (URGN) | UroGen Pharma Ltd (URGN) is an innovative biotechnology company focused on the development of advanced therapies for urological diseases... | URGN competitors |
| Vera Therapeutics Inc (VERA) | Vera Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immune diseases... | VERA competitors |
| Trevi Therapeutics Inc (TRVI) | Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on the development and commercialization of Haduvio to treat serious... | TRVI competitors |
| Precigen Inc (PGEN) | Precigen, Inc. discovers and develops the next generation of cell and gene therapies in the United States. The company is headquartered in Germantown, Maryland. | PGEN competitors |
| Intellia Therapeutics Inc (NTLA) | Intellia Therapeutics, Inc., a genome editing company, is focused on developing therapies. The company is headquartered in Cambridge, Massachusetts. | NTLA competitors |
Frequently Asked Questions About QURE
Who are Uniqure NV's main competitors?
The companies most similar to Uniqure NV include Ultragenyx (RARE), Pharvaris BV (PHVS), Nurix Therapeutics (NRIX), Nuvation Bio (NUVB) and CureVac NV (CVAC), listed from the closest match.
Who is Uniqure NV's biggest competitor?
Pharvaris BV (PHVS) is the largest of the similar companies at $2.36B; Ultragenyx (RARE) is the closest match by business profile, size, sector and industry.
How does QURE stock compare with its competitors?
QURE's P/S is 75.8x against a peer median of 6.0x; its net margin is 0.0% against a peer median of 0.0%.
Which of Uniqure NV's competitors pays a higher dividend?
Uniqure NV pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Uniqure NV bigger than its competitors?
No. Uniqure NV is 6th by market cap among the 13 companies on this page; the largest is Pharvaris BV (PHVS) at $2.36B.
QURE pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors